Literature DB >> 25917253

Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?

Bobby C Liaw1, William K Oh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25917253     DOI： 10.1038/nrclinonc.2015.79

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Daniel P Petrylak; Nicholas J Vogelzang; Nikolay Budnik; Pawel Jan Wiechno; Cora N Sternberg; Kevin Doner; Joaquim Bellmunt; John M Burke; Maria Ochoa de Olza; Ananya Choudhury; Juergen E Gschwend; Evgeny Kopyltsov; Aude Flechon; Nicolas Van As; Nadine Houede; Debora Barton; Abderrahim Fandi; Ulf Jungnelius; Shaoyi Li; Ronald de Wit; Karim Fizazi
Journal:  Lancet Oncol       Date:  2015-03-03       Impact factor: 41.316

2.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

3.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors:  Ian F Tannock; Karim Fizazi; Sergey Ivanov; Camilla Thellenberg Karlsson; Aude Fléchon; Iwona Skoneczna; Francisco Orlandi; Gwenaelle Gravis; Vsevolod Matveev; Sevil Bavbek; Thierry Gil; Luciano Viana; Osvaldo Arén; Oleg Karyakin; Tony Elliott; Alison Birtle; Emmanuelle Magherini; Laurence Hatteville; Daniel Petrylak; Bertrand Tombal; Mark Rosenthal
Journal:  Lancet Oncol       Date:  2013-06-04       Impact factor: 41.316

4.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

5.  Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

Authors:  Chadi Nabhan; Anand Patel; Dana Villines; Kathy Tolzien; Susan K Kelby; Timothy M Lestingi
Journal:  Clin Genitourin Cancer       Date:  2013-10-01       Impact factor: 2.872

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.

Authors:  William L Dahut; James L Gulley; Philip M Arlen; Yinong Liu; Katherine M Fedenko; Seth M Steinberg; John J Wright; Howard Parnes; Clara C Chen; Elizabeth Jones; Catherine E Parker; W Marston Linehan; William D Figg
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

Review 8.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

9.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728
  9 in total
  1 in total

1.  Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens.

Authors:  Jessica J Nunes; Swaroop K Pandey; Anjali Yadav; Sakshi Goel; Bushra Ateeq
Journal:  Neoplasia       Date:  2017-03-19       Impact factor: 5.715
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.